Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is a global medical technology company focused on musculoskeletal health, orthopedic implants and digital and robotic technologies. This news page aggregates company announcements, press releases and market-facing updates so readers can follow how Zimmer Biomet develops and commercializes its orthopedic, trauma and digital care offerings.
Recent news highlights include earnings announcements and conference call webcasts, where Zimmer Biomet reports quarterly financial results and discusses performance across product categories such as knees, hips, sports medicine, extremities, trauma and technology and data, bone cement and surgical. The company also issues updates on its capital allocation, including quarterly cash dividends approved by its Board of Directors.
Zimmer Biomet frequently announces product and technology milestones. Examples include U.S. FDA 510(k) clearance for an enhanced version of its ROSA Knee robotic technology, FDA Breakthrough Device Designation for an iodine-treated total hip replacement system, and launches of new foot and ankle trauma solutions through its Paragon 28 business. The company also reports collaborations and integrations, such as the use of mobility intelligence technology within its mymobility care management platform, and highlights its broader connected care strategy linking robotics, digital platforms and analytics.
Investors and observers can also find updates on Zimmer Biomet’s participation in major healthcare and investor conferences, as well as news related to acquisitions like the merger with Monogram Technologies Inc. Bookmark this page to review the latest official communications from Zimmer Biomet on its orthopedic portfolio, digital and robotic technologies, financial disclosures and strategic initiatives.
Zimmer Biomet Holdings (ZBH) has announced a quarterly cash dividend of $0.24 per share for Q2 2021. This dividend is payable on or about July 30, 2021 to stockholders who are on record as of the close of business on June 28, 2021. The company, a leader in musculoskeletal healthcare, continues to demonstrate its commitment to returning value to its shareholders. Founded in 1927, Zimmer Biomet operates in over 25 countries, selling products in more than 100 countries.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) recently appointed Wilfred van Zuilen as President for the EMEA region and Nitin Goyal, M.D. as Chief Science, Technology and Innovation Officer. These changes aim to strengthen the company's leadership as it transitions through a pivotal business phase. Van Zuilen brings extensive experience from Medtronic, while Dr. Goyal leverages his medical background and digital innovation expertise to enhance Zimmer Biomet's product development and clinical affairs.
Zimmer Biomet Holdings (NYSE: ZBH) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 8, 2021, at 11:20 a.m. ET. The presentation will be made by Chairman and CEO Bryan Hanson and CFO Suky Upadhyay. A live webcast can be accessed on Zimmer Biomet's Investor Relations website, with an archive available post-conference. Founded in 1927, Zimmer Biomet specializes in musculoskeletal healthcare and operates in over 25 countries. For more information, visit zimmerbiomet.com.
Zimmer Biomet Holdings (NYSE: ZBH), a leader in musculoskeletal healthcare, announced that Chairman and CEO Bryan Hanson and CFO Suky Upadhyay will present at the Bernstein's 37th Annual Strategic Decisions Conference on June 2, 2021, at 10:00 a.m. ET. They will also present at the Jefferies Virtual Health Care Conference on June 3, 2021. Live webcasts can be accessed via their Investor Relations website and will be available for replay after the events.
Zimmer Biomet Holdings reported first-quarter net sales of $1.847 billion, a 3.6% increase year-over-year, and net earnings of $198.1 million. Diluted EPS stood at $0.94, with adjusted EPS at $1.71, reflecting a 0.6% rise from the previous year. The company expects a continued positive trend as elective procedures resume post-pandemic. Key highlights include the launch of ZBEdge technologies and FDA clearance for the ROSA® Partial Knee System, alongside leadership appointments aiding in their ongoing transformation.
ZBH announced that President and CEO Bryan Hanson and Executive VP and CFO Suky Upadhyay will present at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021, at 12:30 p.m. ET. The live webcast will be accessible via Zimmer Biomet's Investor Relations website and archived for replay afterward. Founded in 1927, Zimmer Biomet is a leader in musculoskeletal healthcare, providing orthopedic and surgical products globally. The company operates in over 25 countries and sells in more than 100 countries.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) announced FDA 510(k) clearance for the ROSA® Partial Knee System, which enhances robotically-assisted partial knee replacement surgeries. This addition to Zimmer Biomet's ROSA Robotics platform aims to improve patient outcomes and surgical accuracy. The system leverages advanced imaging technology and intraoperative data collection, which can optimize surgery based on individual patient anatomy. With over 50% of the global partial knee market share, Zimmer Biomet continues to lead in musculoskeletal healthcare, emphasizing its commitment to innovative solutions.
Zimmer Biomet Holdings (ZBH) will host its first quarter earnings conference call on May 4, 2021, at 8:30 a.m. ET. An associated news release with financial results will be available earlier that day at 6:30 a.m. ET. The conference call can be accessed via Zimmer Biomet's Investor Relations website, with a digital recording available post-call until July 6, 2021. This call provides an opportunity for investors to evaluate the company's financial performance and future outlook.
Zimmer Biomet Holdings (NYSE: ZBH) launched the ZBEdge™ Connected Intelligence Suite, featuring advanced digital and robotic technologies aimed at enhancing patient outcomes. Key components include the ROSA® Robotics Platform, Signature™ ONE Surgical Planning, and mymobility® with Apple Watch®. This suite integrates pre-, intra-, and post-operative technologies, leveraging data for improved surgical insights. The initiative underscores Zimmer Biomet's commitment to optimizing the patient experience and empowering healthcare professionals through actionable data.
Zimmer Biomet Holdings, Inc. (ZBH) announced important changes in its Executive Leadership Team on March 31, 2021. Lori Winkler has been appointed as the Chief Human Resources Officer (CHRO), having previously served as Group Vice President of Human Resources. Sang Yi has been promoted to Group President for Asia Pacific, a role he has held since June 2015. Both appointments are aimed at strengthening the company's human resources and regional operations as part of its mission to improve patient care globally.